HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2V659E, HER2G660D) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thorac Oncol

Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publisher: Elsevier BV

ISSN (Electronic): 1556-1380

ISSN (Print): 1556-0864

Publication date (Electronic): Mar 2017

Volume: 12

Issue: 3

Affiliations

[1 ] Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: Ignatius.ou@uci.edu.

[2 ] Foundation Medicine, Inc., Cambridge, Massachusetts.

[3 ] Department of Structural Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

[4 ] The Angeles Clinic and Research Institute, Los Angeles, California.

[5 ] Hospital Sao Jose, Sao Paulo, Brazil.

[6 ] Affiliated Oncologists, LLC, Oak Lawn, Illinois.

[7 ] Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee.

[8 ] University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.

[9 ] Foundation Medicine, Inc., Cambridge, Massachusetts; Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

[10 ] Foundation Medicine, Inc., Cambridge, Massachusetts; Albany Medical College, Albany, New York.

[11 ] Cleveland Clinic, Cleveland Clinic Main Campus, Cleveland, Ohio.

Article

Publisher Item ID: S1556-0864(16)33532-8

DOI: 10.1016/j.jtho.2016.11.2224

PubMed ID: 27903463

SO-VID: 4bf307e4-9835-455a-afde-eccda419a82c

History

Keywords: Actionable driver mutation,Afatinib,HER2 G660,HER2 V659,NSCLC,Transmembrane mutation

Data availability:

Keywords: Actionable driver mutation, Afatinib, HER2 G660, HER2 V659, NSCLC, Transmembrane mutation

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

Read this article at

Abstract

Related collections

Inflamed lung in vitro co-culture models

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 37